How can cardiac sarcoidosis be distinguished from cardiac amyloidosis?

Distinguishing Cardiac Sarcoidosis from Cardiac Amyloidosis

The key to differentiating cardiac sarcoidosis from cardiac amyloidosis lies in a systematic approach combining serum screening for monoclonal proteins, cardiac MRI pattern recognition, and disease-specific nuclear imaging—with cardiac MRI showing subendocardial/transmural late gadolinium enhancement (LGE) in amyloidosis versus patchy mid-myocardial/subepicardial LGE in sarcoidosis, followed by confirmatory nuclear imaging (Tc-99m-PYP for ATTR amyloidosis or FDG-PET for cardiac sarcoidosis). 1, 2

Initial Screening: Rule Out Amyloidosis First

Always begin by screening for plasma cell dyscrasia to exclude AL amyloidosis, as this is critical and requires urgent hematology referral if positive 1:

• Serum and urine protein electrophoresis with immunofixation
• Serum free light chain (sFLC) assay with kappa/lambda ratio

This step is mandatory before proceeding with further diagnostic imaging, as both conditions can occasionally show overlapping features, and AL amyloidosis requires immediate specialized treatment 1.

Cardiac MRI: The Primary Differentiating Tool

Cardiac MRI provides the most distinctive patterns to separate these entities 2:

Cardiac Amyloidosis Pattern:

• Concentric biventricular wall thickening (typically >1.2 cm)
• Diffuse subendocardial LGE progressing to transmural pattern
• Low T2 signal on T2-weighted images
• Elevated native T1 and extracellular volume (ECV)
• Global longitudinal strain with apical sparing (base-to-apex gradient)
• Dark blood pool and early myocardial nulling on post-contrast imaging
• Thickening of atria, interatrial septum, and valves

Cardiac Sarcoidosis Pattern:

• Patchy, focal LGE in mid-myocardial or subepicardial distribution
• Predilection for basal septal and lateral LV walls
• High T2 signal (edema) in acute/active disease
• Elevated native T1 and T2 values in active inflammation
• Wall thinning and aneurysms in chronic stage
• Regional wall motion abnormalities

The sensitivity and specificity of MRI are 85% and 92% for cardiac amyloidosis, and 75-100% and 75-77% for cardiac sarcoidosis, respectively 2.

Nuclear Imaging: Disease-Specific Confirmation

For Suspected ATTR Amyloidosis (after excluding AL):

Tc-99m-PYP/DPD/HMDP scintigraphy is highly specific 2, 3:

• Grade 2 or 3 myocardial uptake (equal to or greater than rib uptake) confirms ATTR amyloidosis
• Heart-to-contralateral lung (H/CL) ratio ≥1.5 at 1 hour supports diagnosis
• Must exclude monoclonal protein first, as >20% of AL cases can show uptake
• Both planar and SPECT imaging required to differentiate from blood pool and bone uptake

For Suspected Cardiac Sarcoidosis:

FDG-PET/CT after glucose suppression (high-fat, low-carbohydrate diet, prolonged fasting >12-18 hours) 2:

• Sensitivity 89%, specificity 78% for cardiac sarcoidosis
• Focal increased FDG uptake in areas of active inflammation
• Can quantify disease activity and monitor treatment response
• Ga-67 scintigraphy has lower sensitivity but high specificity

Critical caveat: FDG-PET findings can occasionally be seen in ATTR amyloidosis, leading to diagnostic confusion 4. Always correlate with MRI patterns and clinical context.

Clinical Features That Aid Differentiation

Cardiac Amyloidosis Clues 1:

• Age >60 years (especially for wild-type ATTR)
• Bilateral carpal tunnel syndrome
• Peripheral sensorimotor neuropathy/dysautonomia
• Low-flow, low-gradient aortic stenosis with preserved LVEF
• Low-voltage ECG despite increased wall thickness
• Atrial fibrillation common

Cardiac Sarcoidosis Clues 2, 5, 6:

• Younger age (mean ~50-60 years)
• Ventricular tachycardia (53% vs. 11% in amyloidosis)
• High-grade AV block
• Systemic sarcoidosis (mediastinal lymphadenopathy, lung involvement)
• Higher ICD implantation rates (66% vs. 13%)

Diagnostic Algorithm

1. Clinical suspicion based on heart failure with increased wall thickness or conduction abnormalities
2. Screen for AL amyloidosis (SPEP/UPEP with immunofixation, sFLC)
3. Cardiac MRI to identify characteristic LGE patterns:
   • Subendocardial/transmural → suspect amyloidosis → proceed to Tc-99m-PYP
   • Patchy mid-myocardial/subepicardial → suspect sarcoidosis → proceed to FDG-PET
4. Nuclear imaging confirmation:
   • Positive PYP (Grade 2-3) + negative monoclonal screen = ATTR amyloidosis
   • Positive FDG-PET with focal uptake = cardiac sarcoidosis
5. Endomyocardial biopsy if imaging equivocal or high clinical suspicion despite negative workup 1

Common Pitfalls to Avoid

• Never rely on echocardiography alone—findings are nonspecific and overlap significantly 1
• Do not skip monoclonal protein screening—AL amyloidosis can show PYP uptake and requires urgent hematology referral 1, 3
• Inadequate FDG-PET preparation leads to physiologic myocardial uptake in ~20% of patients, causing false positives 7
• ATTR amyloidosis can occasionally show FDG uptake, mimicking sarcoidosis 4
• Cardiac sarcoidosis can present with diffuse LGE, mimicking amyloidosis 8
• Always correlate imaging with clinical context—isolated imaging findings without clinical correlation can mislead 2, 6

Prognostic Implications

Cardiac amyloidosis: Transmural LGE, elevated troponins, and reduced LVEF predict mortality 2. ATTR patients have more LV thickening and lower LVEF than AL 2.

Cardiac sarcoidosis: LGE presence has a hazard ratio of 32 for lethal events 2. Lower LGE burden at treatment initiation predicts better steroid response 2.